Ensysce Biosciences (ENSC) Projected to Post Earnings on Monday

Ensysce Biosciences (NASDAQ:ENSC) is anticipated to post its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect Ensysce Biosciences to post earnings of ($0.99) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 4:00 PM ET.

Ensysce Biosciences Stock Performance

Shares of ENSC stock opened at $0.62 on Monday. Ensysce Biosciences has a fifty-two week low of $0.31 and a fifty-two week high of $5.72. The firm has a market capitalization of $2.26 million, a PE ratio of -0.10 and a beta of 1.14. The stock’s 50-day simple moving average is $0.76 and its 200-day simple moving average is $1.57.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Adage Capital Partners GP L.L.C. boosted its position in Ensysce Biosciences by 100.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock worth $138,000 after purchasing an additional 75,000 shares in the last quarter. DRW Securities LLC lifted its stake in shares of Ensysce Biosciences by 42.4% in the 4th quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock valued at $91,000 after purchasing an additional 29,336 shares during the period. Citadel Advisors LLC purchased a new stake in Ensysce Biosciences during the third quarter worth $34,000. Finally, Virtu Financial LLC purchased a new stake in Ensysce Biosciences during the third quarter worth $34,000. 5.63% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Ensysce Biosciences in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.